LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
Study Details
Study Description
Brief Summary
This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.
Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This observational study will access routinely acquired radiation therapy treatment data from 300 patients including brain, breast, head and neck, kidney, liver, pancreas, prostate, spine and cardiac anatomic sites. At least 30 patients will be recruited from each anatomic site to enable sufficient data for the markerless tracking method training, testing and validation. The clinical data will be used to develop, train, test and validate a markerless target tracking method.
After the treatment, the ground truth and the variability in the ground truth will be computed. The patient images, the markerless tracking results, the ground truth and the variability will be uploaded to an in-house developed clinical trial learning system. Uploading additional data to the learning system automatically triggers the model building of the deep learning system. In this manner, the learning system gets both more accurate and more robust with each patient accrued. As the patient data accrues, the primary hypothesis of targeting accuracy can be tested.
The developed markerless tracking software will be applied by study personnel to the treatment imaging data for each anatomic site using five-fold cross-validation where 80% of the data is used for training and the remaining unseen 20% of the data is used for testing. Target positions produced by the markerless tracking will be compared with a 'ground truth'.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Brain cancer Patients having radiation therapy for treatment of brain cancer. |
|
Breast cancer Patients having radiation therapy for treatment of breast cancer. |
|
Head and neck cancer Patients having radiation therapy for treatment of head and neck cancer. |
|
Kidney cancer Patients having radiation therapy for treatment of kidney cancer. |
|
Liver cancer Patients having radiation therapy for treatment of liver cancer. |
|
Pancreatic cancer Patients having radiation therapy for treatment of pancreatic cancer. |
|
Prostatic cancer Patients having radiation therapy for treatment of prostate cancer. |
|
Spinal neoplasm Patients having radiation therapy for treatment of spinal cancer. |
|
Cardiac arrhythmia Patients having radiation therapy for treatment of cardiac arrhythmia |
Outcome Measures
Primary Outcome Measures
- Accuracy of markerless tracking [3 years]
Proportion of markerless tracking within 5 mm of the ground truth for each of nine anatomical sites (cohorts)
Secondary Outcome Measures
- Clinical acceptability of markerless tracking system [3 years]
Proportion of radiation therapists considering the markerless tracking system acceptable using a survey
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.
-
Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.
-
Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.
-
Provides written informed consent.
Exclusion Criteria:
- Less than 18 years of age
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Royal North Shore Hospital | Saint Leonards | New South Wales | Australia | 2065 |
2 | Princess Alexandra Hospital | Woolloongabba | Queensland | Australia | 4102 |
3 | Alfred Health | Melbourne | Victoria | Australia | 3000 |
4 | Peter MacCallum Cancer Centre | Melbourne | Victoria | Australia | 3000 |
Sponsors and Collaborators
- University of Sydney
- Princess Alexandra Hospital, Brisbane, Australia
- Calvary Mater Newcastle, Australia
- Western Sydney Local Health District
- Austin Health
- Peter MacCallum Cancer Centre, Australia
Investigators
- Study Chair: Paul Keall, Professor
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IX-2021-DS-LEARN